Abstract: The preset invention relates to preventing, arresting, reversing or treating atherosclerosis, comprising a step of: administering to a subject in need thereof a therapeutically effective amount of a macrophage inflammatory protein-1 beta (MIP-1?) inhibitor.
Type:
Application
Filed:
August 10, 2018
Publication date:
June 4, 2020
Applicants:
NATIONAL YANG-MING UNIVERSITY, TAIPEI VETERANS GENERAL HOSPITAL, VIVASOLIS BIOTECHNOLOGY CO., LTD.